Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
Running, not enrolling · Phase 2 · Has a placebo group
Conditions studied: Prostate Cancer Recurrent
In brief
This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or definitive RT and no distant metastasis or locoregional recurrence. The trial is a randomized placebo-controlled double-blind study of a peptide cancer vaccine (RV001V).
Key facts
- Study ID
- NCT04114825
- Run by
- RhoVac APS
- People needed
- 180
- Starts
- 2019-11-19
- Expected to finish
- 2022-11-01
- Last updated by the study team
- 2021-09-28
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Tampa Bay Medical Research — Clearwater, Florida, United States
- Chesapeake Urology Research Associates — Towson, Maryland, United States
- GU Research Network/Urology Cancer Center — Omaha, Nebraska, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Icahn School of Medicine at Mount Sinai Hospitals — New York, New York, United States
- Carolina Urologic Research Center — Myrtle Beach, South Carolina, United States
- The Urology Place — San Antonio, Texas, United States
- Gent University Hospital — Ghent, Belgium
- CHU de Liège — Liège, Belgium
- Hôpital Erasme — Liège, Belgium
- Aalborg University, Departmen of Urology — Aalborg, Denmark
- Aarhus University Hospital, Department of Urology — Aarhus, Denmark
- Rigshospitalet, Copenhagen Prostate Cancer Center — Copenhagen, Denmark
- Herlev & Gentofte Hospital, Department of Urology — Herlev, Denmark
- Urinvejskirurgisk afdeling, Hospitalsenheden Vest — Holstebro, Denmark
- Odense University Hospital, Deparment of Urology — Odense, Denmark
- Meilahti Tower Hospital — Helsinki, Finland
- Oulu University Hospital — Oulu, Finland
- Seinajoki Central Hospital — Seinäjoki, Finland
- Tampere University Hospital — Tampere, Finland
- Turku University Hospital — Turku, Finland
- University Hospital Dresden — Dresden, Germany
- Urologicum Duisburg — Duisburg, Germany
- Urologische Praxis Dr. Wolfgang Warnack — Hagenow, Germany
- Urologische Praxis. M. Markov — Halle, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.